215 related articles for article (PubMed ID: 3359437)
1. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
[TBL] [Abstract][Full Text] [Related]
3. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
Friedman HS; Colvin OM; Griffith OW; Lippitz B; Elion GB; Schold SC; Hilton J; Bigner DD
J Natl Cancer Inst; 1989 Apr; 81(7):524-7. PubMed ID: 2921776
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
6. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
Berger SJ; Gosky D; Zborowska E; Willson JK; Berger NA
Cancer Res; 1994 Aug; 54(15):4077-83. PubMed ID: 8033140
[TBL] [Abstract][Full Text] [Related]
7. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
8. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
9. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
[TBL] [Abstract][Full Text] [Related]
10. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
[TBL] [Abstract][Full Text] [Related]
11. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
Guichard M; Lespinasse F; Malaise EP
Radiat Res; 1986 Jan; 105(1):115-25. PubMed ID: 3945723
[TBL] [Abstract][Full Text] [Related]
12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
Laskowitz DT; Elion GB; Dewhirst MW; Griffith OW; Savina PM; Blum MR; Prescott DM; Bigner DD; Friedman HS
Radiat Res; 1992 Feb; 129(2):218-23. PubMed ID: 1734453
[TBL] [Abstract][Full Text] [Related]
14. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
Friedman HS; Skapek SX; Colvin OM; Elion GB; Blum MR; Savina PM; Hilton J; Schold SC; Kurtzberg J; Bigner DD
Cancer Res; 1988 Oct; 48(19):5397-402. PubMed ID: 3416297
[TBL] [Abstract][Full Text] [Related]
15. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Soble MJ; Dorr RT
Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
[TBL] [Abstract][Full Text] [Related]
16. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.
Skapek SX; Colvin OM; Griffith OW; Groothuis DR; Colapinto EV; Lee Y; Hilton J; Elion GB; Bigner DD; Friedman HS
Biochem Pharmacol; 1988 Nov; 37(22):4313-7. PubMed ID: 3196356
[TBL] [Abstract][Full Text] [Related]
17. Effect of DL-buthionine-S,R-sulfoximine on the growth of EMT6 and RIF mouse tumors.
Miller AC; Henderson BW
J Natl Cancer Inst; 1986 Aug; 77(2):505-10. PubMed ID: 3461211
[TBL] [Abstract][Full Text] [Related]
18. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
19. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
20. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms.
Lüthen RE; Neuschwander-Tetri BA; Niederau C; Ferrell LD; Grendell JH
Int J Pancreatol; 1994 Aug; 16(1):31-6. PubMed ID: 7528760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
